Monte Rosa Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
GLUE$10.50-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated statements of operations and comprehensive loss
| Year ended December 31, | ||
|---|---|---|
| (in thousands, except share and per share amounts) | 2024 | 2023 |
| Collaboration revenue | $75,622 | $— |
| Operating expenses: | ||
| Research and development | 121,563 | 111,272 |
| General and administrative | 35,171 | 32,039 |
| Total operating expenses | 156,734 | 143,311 |
| Loss from operations | (81,112) | (143,311) |
| Other income (expense): | ||
| Interest income | 10,566 | 9,334 |
| Foreign currency exchange gain (loss), net | 416 | (930) |
| Gain on disposal of fixed assets | — | 24 |
| Loss on sale of marketable securities | — | (131) |
| Total other income | 10,982 | 8,297 |
| Net loss before income taxes | (70,130) | (135,014) |
| Provision for income taxes | (2,570) | (338) |
| Net loss | $(72,700) | $(135,352) |
| Net loss per share—basic and diluted | $(0.98) | $(2.63) |
| Weighted-average number of shares outstanding used in computing net loss per common share—basic and diluted | 73,910,026 | 51,396,961 |
| Comprehensive loss: | ||
| Net loss | $(72,700) | $(135,352) |
| Other comprehensive income: | ||
| Provision for pension benefit obligation | (802) | (1,369) |
| Unrealized gain on available-for-sale securities | 170 | 397 |
| Comprehensive loss | $(73,332) | $(136,324) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.